Skip to main content
SpringerLink
Log in

Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus

  • Therapy In Practice
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Antimalarials have been used to treat cutaneous and systemic lupus erythematosus (LE) for decades. Although controlled studies comparing the efficacy of antimalarials versus placebo and other treatments are generally lacking, many case reports and series support the therapeutic efficacy of these agents in treating both LE-specific and -nonspecific skin lesions. Currently, the two most frequently used antimalarial agents are chloroquine and hydroxychloroquine. There may be a delay of weeks to months in the onset of therapeutic effects of antimalarials when treating LE. Smoking appears to inhibit the therapeutic efficacy of antimalarials when treating cutaneous LE. Antimalarials have been associated with a number of potentially serious adverse effects, including irreversible loss of vision. The aim of this review is to discuss the many facets of antimalarials that will help clinicians optimally utilize these agents when treating cutaneous LE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2

Similar content being viewed by others

References

  1. Payne JF. A postgraduate lecture on lupus erythematosus. Clin J 1894; 4: 223–9

    Google Scholar 

  2. Tsakonas E, Joseph L, Esdaile JM, et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus: the Canadian Hydroxychloroquine Study Group. Lupus 1998; 7: 65–7

    Google Scholar 

  3. Ritschel WA, Hammer GV, Thompson GA. Pharmacokinetics of antimalarials and proposals for dosage regimens. Int J Clin Pharmacol Biopharm 1978; 16: 395–401

    PubMed  CAS  Google Scholar 

  4. Laaksonen AL, Koskiahde V, Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scand J Rheumatol 1974; 3: 103–8

    Article  PubMed  CAS  Google Scholar 

  5. McChesney EW, Rothfield NF. Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964; 7: 328–9

    Google Scholar 

  6. Feldmann R, Salomon D, Saurat JH. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus. Dermatology 1994; 189: 425–7

    Article  PubMed  CAS  Google Scholar 

  7. Lipsker D, Piette JC, Cacoub P, et al. Chloroquine-quinacrine association in resistant cutaneous lupus. Dermatology 1995; 190: 257–8

    Article  PubMed  CAS  Google Scholar 

  8. Toubi E, Rosner I, Rozenbaum M, et al. The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 2000; 9: 92–5

    Article  PubMed  CAS  Google Scholar 

  9. Koranda FC. Antimalarials. J Am Acad Dermatol 1981; 4: 650–5

  10. Sjolin-Forsberg G, Berne B, Blixt C, et al. Chloroquine phosphate: a long-term follow up of drug concentration in skin suction blister fluid and plasma. Acta Derm Venereol 1993; 73: 426–9

    PubMed  CAS  Google Scholar 

  11. Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 1985; 64: 285–95

    Article  PubMed  CAS  Google Scholar 

  12. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471–5

    Article  PubMed  CAS  Google Scholar 

  13. Gilliam JN, Sontheimer RD. Skin manifestations of SLE. Clin Rheum Dis 1982; 8: 207–18

    PubMed  CAS  Google Scholar 

  14. McCauliffe DP. Cutaneous lupus erythematosus. Semin Cutan Med Surg 2001; 20: 14–26

    Article  PubMed  CAS  Google Scholar 

  15. The Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. N Engl J Med 1991; 324: 150–4

    Article  Google Scholar 

  16. The Canadian Hydroxychloroquine Study Group. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus’ erythematosus. Lupus 1997; 7: 80–5

    Google Scholar 

  17. Sontheimer RD, Provost TT. Cutaneous manifestations of lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 5th ed. Baltimore (MD): Williams & Wilkins, 1997: 569–23

    Google Scholar 

  18. Sontheimer RD, Thomas JR, Gilliam JM. Subacute cutaneous lupus erythematosus. Arch Dermatol 1979; 115: 1409–15

    Article  PubMed  CAS  Google Scholar 

  19. Cardinali C, Caproni M, Baenacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus: the Italian experience. Lupus 2000; 9: 417–23

    Article  PubMed  CAS  Google Scholar 

  20. Furner BB. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 1990; 29: 542–7

    Article  PubMed  CAS  Google Scholar 

  21. Ruzicka T, Bieber T, Meurer M. Subacute cutaneous lupus erythematosus: clinical aspects, immunology and therapy. Wien Klin Wochenschr 1987; 99: 802–7

    PubMed  CAS  Google Scholar 

  22. Jessop S, Whitelaw D, Jordan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001; 1: XXCD 002954

    Google Scholar 

  23. Callen JP. Chronic cutaneous lupus erythematosus. Clinical, laboratory therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118: 412–6

    Article  PubMed  CAS  Google Scholar 

  24. Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol 1997; 24: 569–72

    PubMed  CAS  Google Scholar 

  25. Morgan KW, Callen JP. Calcifying lupus panniculitis in a patient with subacute cutaneous lupus erythematosus: response to diltiazem and chloroquine. J Rheumatol 2001; 28: 129–32

    Google Scholar 

  26. Harvey S, Pineda R, Shore JW, et al. Hypertrophic discoid lupus erythematosus of conjunctiva. Am J Ophthalmol 1999; 127: 604–5

    Article  Google Scholar 

  27. Donzis PB, Insler MS, Buntin DM, et al. Discoid lupus erythematosus involving the eyelids. Am J Ophthalmol 1984; 98: 32–6

    Article  PubMed  CAS  Google Scholar 

  28. Pock L, Petrovska P, Becvar R, et al. Verrucous form of chilblain lupus erytheto matosus. J Eur Acad Dermatol Venereol 2001; 15: 448–51

    Article  PubMed  CAS  Google Scholar 

  29. Dubois EL. Antimalarials in the management of discoid and systemic lupus erythematosus. Semin Arthritis Rheum 1978; 8: 33–51

    Article  PubMed  CAS  Google Scholar 

  30. Werth V, Franks A. Treatment of discoid skin lesions with azathioprine. Arch Dermatol 1986; 122: 746–7

    Article  PubMed  CAS  Google Scholar 

  31. Wallace DJ. Antimalarials: the “real” advance in lupus. Lupus 2001; 10: 385–7

    Article  PubMed  CAS  Google Scholar 

  32. Wallace DJ. Antimalarial therapies. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. 5th ed. Baltimore (MD): Williams & Wilkins, 1997: 1117–40

    Google Scholar 

  33. Rahman P, Gladmann DD, Urowitz MB. Efficacy of antimalarial therapy in cutaneous lupus in smokers versus non-smokers. J Rheumatol 1998; 25: 1716–9

    PubMed  CAS  Google Scholar 

  34. Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol 2000; 42: 983–7

    Article  PubMed  CAS  Google Scholar 

  35. Miller RG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990; 9: 125–35

    PubMed  CAS  Google Scholar 

  36. Polet T. The effects of lysosomotrophic amines on protein degradation, migration of nonhistone proteins to the nucleus, and cathepsin D in lymphocytes. J Cell Physiol 1985; 122: 415–23

    Article  PubMed  CAS  Google Scholar 

  37. Wanwimolruk S, Wong SM, Coville PF, et al. Cigarette smoking enhances the elimination of quinine. Br J Clin Pharmacol 1993; 36: 610–4

    Article  PubMed  CAS  Google Scholar 

  38. Hardy CJ, Palmer BP, Muir KR, et al. Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study. Ann Rheum Dis 1998; 57: 451–5

    Article  PubMed  CAS  Google Scholar 

  39. Nagata C, Fujita S, Iwata H, et al. Systemic lupus erythematosus: a case-control epidemiologic study in Japan. Int J Dermatol 1995; 34: 333–7

    Article  PubMed  CAS  Google Scholar 

  40. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am 1994; 20: 243–63

    PubMed  CAS  Google Scholar 

  41. Johansson E, Kanerva L, Niemi KM, et al. Diffuse soft tissue calcifications (calcinosis cutis) in patient with discoid lupus erythematosus. Clin Exp Dermatol 1988; 13: 193–6

    Article  PubMed  CAS  Google Scholar 

  42. Marzano AV, Kolesnikova LV, Gasparini G, et al. Dystrophic calcinosis cutis in subacute cutaneous lupus. Dermatology 1999; 90: 90–2

    Article  Google Scholar 

  43. Wozniacka A, Robak E, Sysa-Jedrzejowska A, et al. The influence of chloroquine treatment on minimal erythema dose measurements in systemic lupus erythematosus patients [abstract]. J Invest Dermatol 2002; 3: 763

    Google Scholar 

  44. Nishijima C, Hatta N, Inaoki M, et al. Urticarial vasculitis in systemic lupus erythematosus: fair response to prednisolone/dapsone and persistent hypocomplementemia. Eur J Dermatol 1999; 9: 54–6

    PubMed  CAS  Google Scholar 

  45. Malcangi G, Brandozzi G, Giangiacomi M, et al. Bullous SLE: response to methotrexate and relationship with disease activity. Lupus 2003; 12: 63–6

    Article  PubMed  CAS  Google Scholar 

  46. Yung A, Oakley A. Bullous systemic lupus erythematosus. Australas J Dermatol 2000; 41: 234–7

    Article  PubMed  CAS  Google Scholar 

  47. Krim E, Noblesse I, Beylot Barry M, et al. Bullous localization of a lupus erythematosus induced by radiotherapy. Ann Dermatol Venereol 2002; 129: 1307–9

    PubMed  CAS  Google Scholar 

  48. 48. Fowler Jr JF, Callen JP. Cutaneous mucinosis associated with lupus erythematosus. J Rheumatol 1984; 11: 380–3

    PubMed  Google Scholar 

  49. Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus; a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033–41

    Article  PubMed  CAS  Google Scholar 

  50. Fox JN, Klapman MH, Rowe L. Lupus profundus in children: treatment with hydroxychloroquine. J Am Acad Dermatol 1987; 16: 839–44

    Article  PubMed  CAS  Google Scholar 

  51. Ziering CL, Rabinowitz LG, Esterly NB. Antimalarials for children: indications, toxicities, and guidelines. J Am Acad Dermatol 1993; 28: 634–70

    Article  Google Scholar 

  52. Magana-Garcia M. Antimalarials for children [letter]. J Am Acad Dermatol 1994; 3: 510

    Article  Google Scholar 

  53. Khamashta MA, Buchanan NM, Hughes GR. The use of hydroxychloroquine in lupus pregnancy: the British experience. Lupus 1996; 5: S65–6

    Article  PubMed  CAS  Google Scholar 

  54. Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double blind and placebo-controlled study. Lupus 2001; 10: 401–4

    Article  PubMed  CAS  Google Scholar 

  55. Costedoat-Chalumeau N, Amoura Z, Duhaut P, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 2004; 50: 3056–7

    Article  Google Scholar 

  56. Tett SE, Cutler DJ, Day RO, et al. A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers. Br J Clin Pharmacol 1988; 26: 303

    Article  PubMed  CAS  Google Scholar 

  57. Petri M. Thrombosis and systemic lupus erythematosus; the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996; 25: 191–3

    Article  PubMed  CAS  Google Scholar 

  58. Rynes RI. Antimalarials: is re-evaluation needed? J Clin Rheumatol 1998; 4: 50–1

    Article  PubMed  CAS  Google Scholar 

  59. Hobbs HE, Eadie SP, Somerville F. Ocular lesions after treatment with chloroquine. Br J Ophthalmol 1961; 45: 284–97

    Article  PubMed  CAS  Google Scholar 

  60. Maksymowych W, Russell AS. Antimalarials in rheumatology: efficacy and safety. Semin Arthritis Rheum 1987; 16: 206–21

    Article  PubMed  CAS  Google Scholar 

  61. Lozier JR, Friedlaender MH. Complications of antimalarial therapy. Int Ophthalmol Clin 1989; 29: 172–8

    Article  PubMed  CAS  Google Scholar 

  62. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1207 patients in a large multicenter outpatient practice. Arthritis Rheum 1997; 40: 1482–6

    Article  PubMed  CAS  Google Scholar 

  63. Mavrikakis I, Mavrikakis E. Are evidence-based guidelines being followed for the monitoring of ocular toxicity of hydroxychloroquine? A nationwide survey of practice amongst consultant rheumatologists and implications for clinical governance. Rheumatology 2004; 43: 1057–8

    Article  PubMed  CAS  Google Scholar 

  64. Araiza-Casillas R, Cardenas F, Morales Y, et al. Factors associated with chloroquine-induced retinopathy in rheumatic diseases. Lupus 2004; 13: 621

    Article  Google Scholar 

  65. Neubauer AS, Samari-Kermani K, Schaller U, et al. Detecting chloroquine retinopathy: electro-oculogram versus colour vision. Br J Ophthalmol 2003; 87: 902–8

    Article  PubMed  CAS  Google Scholar 

  66. Pluenneke AC, Blomquist PH. Utility of red Amsler grid screening in a rheumatology clinic. J Rheumatol 2004; 31: 1754–5

    PubMed  Google Scholar 

  67. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 723–31

    Article  Google Scholar 

  68. Sontheimer RD. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus. Arch Dermatol 2000; 136: 1044–9

    Article  PubMed  CAS  Google Scholar 

  69. Trenholme GM, Carson PE. Therapy and prophylaxis of malaria. JAMA 1978; 240: 2293–5

    Article  PubMed  CAS  Google Scholar 

  70. Custer RP. Aplastic anemia in soldiers treated with Atabrine (quinacrine). Am J Med Sci 1946; 212: 211–24

    PubMed  CAS  Google Scholar 

  71. Zuehlke RL, Lillis PJ, Tice A. Antimalarial therapy for lupus erythematosus: an apparent advantage of quinacrine. Int J Dermatol 1981; 20: 57–61

    Article  PubMed  CAS  Google Scholar 

  72. Schmid I, Anasetti C, Petersen FB, et al. Marrow transplantation for severe aplastic anemia associated with exposure to quinacrine. Blut 1990; 61: 52–4

    Article  PubMed  CAS  Google Scholar 

  73. Ward WQ, Walter-Ryan WG, Shehi GM. Toxic psychosis: a complication of antimalarial therapy. J Am Acad Dermatol 1985; 12: 863–5

    Article  PubMed  CAS  Google Scholar 

  74. Evans RL, Khalid S, Kinney JL. Antimalarial psychosis revisited. Arch Dermatol 1984; 120: 765–7

    Article  PubMed  CAS  Google Scholar 

  75. Genel F, Erermis S, Aksu G, et al. Quinacrine-induced psychiatric disturbances in a child with common variable immunodeficiency and chronic giardiasis. Hum Psychopharmacol 2002; 17: 357–9

    Article  PubMed  Google Scholar 

  76. Tristano AG, Falcon L, Wilson M, et al. Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus. Rheum Int 2004; 24: 315–6

    Article  Google Scholar 

  77. Holme SA, Holmes SC. Hydroxychloroquine-induced pruritus. Acta Derm Venereol 1999; 79: 333

    Article  PubMed  CAS  Google Scholar 

  78. Jimenez-Alonso J, Tercedor J, Reche I. Antimalarial drugs and pruritus in patients with lupus erythematosus [letter]. Acta Derm Venereol 2000; 80: 458

    PubMed  CAS  Google Scholar 

  79. Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol 2004; 50: 650–1

    Article  PubMed  Google Scholar 

  80. Litt JZ. Litt’s drug eruption manual. 9th ed. New York: Parthenon Publishing, 2003: 91

    Google Scholar 

  81. Wallace DJ. The use of quinacrine (Atabrine) in rheumatic diseases: a re-examination. Semin Arthritis Rheum 1989; 18: 282–97

    Article  PubMed  CAS  Google Scholar 

  82. Metayer I, Balguerie X, Courville P, et al. Photodermatosis induced by hydroxychloroquine: 4 cases. Ann Dermatol Venereol 2001; 128: 729–31

    PubMed  CAS  Google Scholar 

  83. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol 2002; 138: 1231–3

    Article  PubMed  Google Scholar 

  84. Verny C, Gennes C, Sebastien P, et al. Heart conduction disorders in long-term treatment with chloroquine: two new cases. Presse Med 1992; 21: 800–4

    PubMed  CAS  Google Scholar 

  85. Physicians desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 3008

  86. Physicians desk reference. 59th ed. Montvale (NJ): Thomson PDR, 2005: 2984

  87. Marquardt K, Albertson TE. Treatment of hydroxychloroquine overdose. Am J Emerg Med 2001; 19: 420–4

    Article  PubMed  CAS  Google Scholar 

  88. Harris L, Downar E, Shaikh NA, et al. Antiarrhythmic potential of chloroquine: new use for an old drug. Can J Cardiol 1988; 4: 295–300

    PubMed  CAS  Google Scholar 

  89. Seidman P, Albertioni F, Beck O, et al. Chloroquine reduces the bioavailability of methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1994; 37: 830–3

    Article  Google Scholar 

  90. McElnay JC, Sidahmed AM, D’Arcy PF. Examination of the chloroquine-kaolin drug absorption interaction using the buccal partitioning model. J Clin Hosp Pharm 1982; 7: 269–73

    PubMed  CAS  Google Scholar 

  91. Ette EI, Brown-Awala EA, Essien EE. Chloroquine elimination in humans: effect of low-dose cimetidine. J Clin Pharmacol 1987; 27: 813–6

    PubMed  CAS  Google Scholar 

  92. Algharably N, Owler D, Lamb JF. The rate of uptake of cardiac glycosides into human cultured cells and the effects of chloroquine on it. Biochem Pharmacol 1986; 35: 3571–81

    Article  PubMed  CAS  Google Scholar 

  93. Sieb JP, Milone M, Engel AG. Effects of the quinoline derivatives quinine, quinidine, and chloroquine on neuromuscular transmission. Brain Res 1996; 712: 179–89

    Article  PubMed  CAS  Google Scholar 

  94. Shieh S, Cohen JL, Lim HW. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol 2000; 42: 645–52

    PubMed  CAS  Google Scholar 

  95. Makin AJ, Wendon J, Fitt S, et al. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994; 35: 569–70

    Article  PubMed  CAS  Google Scholar 

  96. Fries JF, Singh G, Lenert L, et al. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1611–9

    Article  PubMed  CAS  Google Scholar 

  97. Browning DJ. Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity. Am J Opthalmol 2002; 133: 649–56

    Article  CAS  Google Scholar 

  98. Fox R, Dixon R, Guarrasi V, et al. Treatment of primary Sjogren’s syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus 1996; 5: S31–6

    Article  PubMed  Google Scholar 

  99. Wolf R, Ruocco V. Triggered psoriasis. Adv Exp Med Biol 1999; 455: 221–5

    Article  PubMed  CAS  Google Scholar 

  100. Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol 2000; 27: 2927–31

    PubMed  CAS  Google Scholar 

  101. Desta M, Tadesse A, Gebre N, et al. Controlled trial of hydroxychloroquine in schizophrenia. J Clin Psychopharmacol 2002; 22: 507–10

    Article  PubMed  CAS  Google Scholar 

  102. Wozniacka A, Carter A, McCauliffe DP. Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002; 11: 71–81

    Article  PubMed  CAS  Google Scholar 

  103. Landewe RB, Miltenburg AM, Breedveld FC, et al. Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CD8 positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353–7

    PubMed  CAS  Google Scholar 

  104. Salmeron G, Lipsky PE. Immunosuppressive potential of antimalarials. Am J Med 1983; 18: 19–24

    Article  Google Scholar 

  105. Sjolin-Forsberg G, Berne B, Eggelte TA, et al. In situ localization of chloroquine and immunohistological studies in UVB-irradiated skin of photosensitive patients. Acta Derm Venereol 1995; 75: 228–31

    PubMed  CAS  Google Scholar 

  106. Olczyk K, Drozdz M, Kucharz E, et al. Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus. Med Interne 1984; 22: 221–5

    PubMed  CAS  Google Scholar 

  107. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996; 5: S4–S10

    Article  PubMed  CAS  Google Scholar 

  108. Ruzicka T, Printz M. Arachidonic acid metabolism in guinea pig skin: effects of chloroquine. Agents Actions 1982; 12: 527–9

    Article  PubMed  CAS  Google Scholar 

  109. Sperber K, Quraishi H, Kalb TH, et al. Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1) and IL-6 in human monocytes and T cells. J Rheumatol 1993; 20: 803–8

    PubMed  CAS  Google Scholar 

  110. Housman TS, Jorizzo JL, McCarty MA, et al. Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus. Arch Dermatol 2003; 139: 50–4

    Article  PubMed  CAS  Google Scholar 

  111. Kanekura T, Yoshii N, Terasaki K, et al. Efficacy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148: 353–6

    Article  PubMed  CAS  Google Scholar 

  112. Yoshimasu T, Ohtani T, Sakamoto T, et al. Topical FK506 (tacrolimus) therapy for facial erythematous lesions of cutaneous lupus erythematosus and dermatomyositis. Eur J Dermatol 2002; 12: 50–2

    PubMed  Google Scholar 

  113. Gerdsen R, Wenzel I, Uerlich M, et al. Successful treatment of chronic discoid lupus erythematosus of the scalp with imiquimod. Dermatology 2002; 205: 416–8

    Article  PubMed  Google Scholar 

  114. Lampropoulos CE, Sangle S, Harrison P, et al. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Rheumatology (Oxford) 2004; 43(11): 1383–5

    Article  CAS  Google Scholar 

  115. Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol 2004; 51(3): 407–10

    Article  PubMed  Google Scholar 

  116. Hall RP, Lawley TJ, Smith HR, et al. Bullous eruption of systemic lupus erythematosus: dramatic response to dapsone therapy. Ann Intern Med 1982; 97: 165–70

    PubMed  CAS  Google Scholar 

  117. Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapyWidespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35: 313–5

    Article  PubMed  CAS  Google Scholar 

  118. Neri R, Mosca M, Bernacchi E, et al. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with Dapsone. Lupus 1999; 8: 240–3

    Article  PubMed  CAS  Google Scholar 

  119. Shornick JK, Formica N, Parke AL. Isotretinoin for refractory lupus erythematosus. J Am Acad Dermatol 1991; 24: 49–52

    Article  PubMed  CAS  Google Scholar 

  120. Ruzicka T, Sommerburg C, Goerz G, et al. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513–8

    Article  PubMed  CAS  Google Scholar 

  121. Arbiser JL, Moschella SL. Clofazimine: A revive of its medical uses and mechanfor isms of action. J Am Acad Dermatol 1995; 32: 241–7

    Article  PubMed  CAS  Google Scholar 

  122. Tsokos GC, Caughman SW, Kleppel JH. Successful treatment of generalized discoid skin lesions with azathioprine. Arch Dermatol 1985; 121: 1323–5

    Article  PubMed  CAS  Google Scholar 

  123. Boehm IB, Boehm GA, Bauer R. Management of cutaneous lupus erythematosus with low-dose methotrexate: indication for modulation of inflammatory mechresistant anisms. Rheumatol Int 1998; 18: 59–62

    Article  PubMed  CAS  Google Scholar 

  124. Bohm I, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194: 307–8

    Article  PubMed  CAS  Google Scholar 

  125. Peter RU, Ruzicka T. Cyclosporin A in the therapy of inflammatory dermatoses. Hautarzt 1992; 43: 687–4

    PubMed  CAS  Google Scholar 

  126. Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral gold compound (auranofin). Br J Dermatol 1986; 115: 211–6

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Department of Dermatology, Medical University of Lodz, Krzemieniecka, Poland

    Anna Wozniacka

  2. Rutland Skin Center, 3 Mahoney Avenue, Rutland, Vermont, VT 05701, USA

    Daniel P. McCauliffe

Authors
  1. Anna Wozniacka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel P. McCauliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel P. McCauliffe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wozniacka, A., McCauliffe, D.P. Optimal Use of Antimalarials in Treating Cutaneous Lupus Erythematosus. Am J Clin Dermatol 6, 1–11 (2005). https://doi.org/10.2165/00128071-200506010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200506010-00001

Keywords

Search

Navigation